Dyslipidemia in human kidney transplant recipients receiving cyclosporine and tacrolimus is associated with different expression of CD36 on peripheral blood monocytes

Transplantation Proceedings

Volumn 43, Issue 5, 2011, Pages 1612-1615

  Jiang, Y ^a   Xie, X B ^b   Peng, L K ^b   Peng, F H ^b   Lan, G B ^b   Wang, Y ^b   Yu, S J ^b   Fang, C H ^b  

^a Central Hospital of Shaoyang   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CD36 ANTIGEN; CYCLOSPORIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS;

ADOLESCENT; ADULT; ANTIGEN EXPRESSION; ARTICLE; CHILD; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DYSLIPIDEMIA; FEMALE; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DONOR; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; LIPID BLOOD LEVEL; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RELATIVE; SCHOOL CHILD; SIDE EFFECT;

ADULT; ANTIGENS, CD36; CYCLOSPORINE; DYSLIPIDEMIAS; FEMALE; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MONOCYTES; TACROLIMUS;

EID: 79959406680     PISSN: 00411345     EISSN: 18732623     Source Type: Journal    
DOI: 10.1016/j.transproceed.2011.03.015     Document Type: Article

References (14)

1. K.L. Womer, J.P. Vella, and M.H. Sayegh Chronic allograft dysfunction: mechanisms and new approaches to therapy Semin Nephrol 20 2000 126
2. Haftberan, and M.D. Sundaram Case 4: cardiovascular risk in renal transplantation Transplantation 75 2003 1610
3. Q. Li, D. Wang, and Y. Wang Simvastatin down regulates mRNA expression of RANTES and CCR5 in posttransplant renal recipients with hyperlipidemia Transplant Proc 38 2006 2899
4. S. Akiba, Y. Mukaida, and K. Hane Group IVA phospholipase A2-mediated production of fibronectin by oxidized LDL in mesangial cells Kidney Int 70 2006 1013
5. Y. Tone, S. Yukawa, and Z. Varghese Lyosphosphotidylcholine induces platelet-derived growth factor gene expression in a human mesangial cell line Kidney Int 71 suppl 1999 S182
6. A. Mathis, S. David, and S. Gary Insights into cyslosporine A-induced atherosclerotic risk in transplant recipients: macrophage scavenger receptor regulation Transplantation 77 2004 497
7. E. Matsuura, K. Kobayashi, and M. Tabuchi Oxidative modification of low-density lipoprotein and immune regulation of atherosclerosis Prog Lipid Res 45 2006 466
8. A. Roy, N. Kneteman, and L. Lilly Tacrolimus as intervention in the treatment of hyperlipidemia after liver transplant Transplantation 82 2006 494
9. N. Sugioka, T. Kokuhu, and M. Okamoto Effect of plasma lipid on pharmacokinetics of cyclosporin and its relationship with plasma prednisolone level in renal transplant patients J Pharm Pharmacol 58 2006 1193
10. T. Rubic, and R.L. Lorenz Downregulated CD36 and OxLDL uptake and stimulated ABCA1/G1 and cholesterol efflux as anti-atherosclerotic mechanisms of interleukin-10 Cardiovasc Res 69 2006 527
11. N.A. Abumrad, M. Ajmal, and K. Pothakos CD36 expression and brain function: does CD36 deficiency impact learning ability Postaglandins Other Lipid Mediat 77 2005 77
12. Y. Tan, Z. Mo, and G. Yi CD36 expression and oxLDL uptake in the early stage of atherosclerosis Chem Life 25 2005 7
13. A. Mathis, S. David, and S. Gary Effect of tacrolimus on the expression of macrophage scavenger and nuclear hormone receptors in THP-1-derived human macrophages Transplantation 77 2004 1281
14. J. Han, X. Zhou, and T. Yokoyama Pitavastatin downregulates expression of the macrophage type B scavenger receptor, CD36 Circulation 109 2004 790